4.7 Article

Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma

期刊

PHARMACOLOGICAL RESEARCH
卷 178, 期 -, 页码 -

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2022.106181

关键词

Hepatitis B virus; HBV reactivation; Rheumatic disease; Hepatocellular carcinoma; Disease-modifying antirheumatic drugs

资金

  1. NSFC [81802504]
  2. International Innovation Cooperation Project of Sichuan Science and Technology Bureau [2022YFH0005]
  3. Science and Technology Innovation Project of Chengdu, China [2021-YF05-00225-SN]
  4. Sichuan Medical Association [Q19037]
  5. Science and Technology Bureau of Sichuan Province for Outstanding Young Talent [2020JDJQ0067]
  6. Pelotonia Postdoc Fellowship
  7. OSU Department of Radiation-Oncology Basic Research seed grant

向作者/读者索取更多资源

This review summarizes the risk of HBV reactivation and medication management plan for HBV carriers, especially rheumatic patients, during rheumatoid therapy. It also provides preventive strategies for HBV reactivation-induced liver diseases, particularly cirrhosis and hepatocellular carcinoma (HCC). These findings are significant for developing treatments for rheumatic patients and preventing HBV-related liver diseases.
To date, an estimated 300 million people worldwide have been infected with chronic hepatitis B virus (HBV). Although anti-HBV therapies have improved the long-term survival profile of chronic carriers, viral reactivation still poses a significant challenge for preventing HBV-related hepatitis, hepatocellular carcinoma (HCC), and death. Immuno-modulating drugs, which are widely applied in managing rheumatic conditions, are commonly associated with HBV reactivation (HBVr) as a result of drug-induced immune suppression. However, there are few reports on the risk of HBVr and the medication management plan for HBV carriers, especially rheumatic patients. In this review, we summarize immuno-modulating drug-induced HBVr during rheumatoid therapy and its preventive strategies for HBVr-induced liver diseases, especially cirrhosis and HCC. These findings will assist with developing treatments for rheumatic patients, and prevent HBV-related cirrhosis and HCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据